---

Participate in a Groundbreaking Clinical Trial in Phoenix, Arizona with Arizona Neuroscience Research

Are you or a loved one living with epilepsy and looking for new treatment options? Arizona Neuroscience Research in Phoenix, AZ, is conducting a clinical trial for Cenobamate monotherapy, an innovative approach to managing focal onset seizures. This is a unique opportunity to access cutting-edge treatment while contributing to scientific advancement in epilepsy care.

About the Clinical Trial

This clinical study aims to evaluate the effectiveness of Cenobamate as a monotherapy for individuals diagnosed with focal onset seizures. Participants will receive expert care from top neurologists and researchers while gaining potential access to new treatment options.

Key benefits of joining the trial:
✅ Access to leading neurology research in Arizona
✅ Close monitoring and expert medical care
✅ Potential relief from epileptic seizures
✅ Compensation for time and travel

Who Can Participate?

You may qualify if you:
🔹 Are 18 years or older
🔹 Have been diagnosed with focal onset seizures
🔹 Are currently taking seizure medications but are open to new treatment options

Eligibility will be determined after an initial screening by our medical team.

Why Choose Arizona Neuroscience Research?

Located in Phoenix, Arizona, we are at the forefront of neurological research and clinical trials. Our team is dedicated to improving patient outcomes through advanced treatment options and state-of-the-art medical studies.

🌵 Convenient Location – Serving the greater Phoenix metro area
💡 Expert Neurologists – Specialized in epilepsy and seizure disorders
🔬 Innovative Research – Access to the latest breakthroughs in neuroscience

How to Enroll

If you or someone you know is interested in participating, contact us today!

📞 Call: (480) 210-8723 
📩 Email: [email protected]
🌐 Visit: https://azneuroscienceresearch.com/

Spots are limited, so don’t miss this opportunity to explore a new path to seizure management!

🔗 Tag & Share: Help us spread the word to those who may benefit!